JP2019507185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507185A5 JP2019507185A5 JP2018559177A JP2018559177A JP2019507185A5 JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5 JP 2018559177 A JP2018559177 A JP 2018559177A JP 2018559177 A JP2018559177 A JP 2018559177A JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- phenyl
- membered heterocyclic
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCl1(=C)=CC=C(CNC(c2n[o]cc2)=CC(c(nc2N(*)*)ncc2F)=[N+])C=C1 Chemical compound CCl1(=C)=CC=C(CNC(c2n[o]cc2)=CC(c(nc2N(*)*)ncc2F)=[N+])C=C1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289463P | 2016-02-01 | 2016-02-01 | |
| US62/289,463 | 2016-02-01 | ||
| US201662398872P | 2016-09-23 | 2016-09-23 | |
| US62/398,872 | 2016-09-23 | ||
| PCT/US2017/015749 WO2017136309A1 (en) | 2016-02-01 | 2017-01-31 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507185A JP2019507185A (ja) | 2019-03-14 |
| JP2019507185A5 true JP2019507185A5 (enExample) | 2020-03-12 |
| JP7098214B2 JP7098214B2 (ja) | 2022-07-11 |
Family
ID=58018271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559177A Active JP7098214B2 (ja) | 2016-02-01 | 2017-01-31 | 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11357777B2 (enExample) |
| EP (1) | EP3411026B1 (enExample) |
| JP (1) | JP7098214B2 (enExample) |
| KR (1) | KR20180104123A (enExample) |
| CN (2) | CN108697678A (enExample) |
| AU (1) | AU2017216429B2 (enExample) |
| BR (1) | BR112018015718A2 (enExample) |
| CA (1) | CA3012001A1 (enExample) |
| IL (1) | IL260701B (enExample) |
| MX (1) | MX386216B (enExample) |
| WO (1) | WO2017136309A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016044446A2 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| AU2017216429B2 (en) | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| IL271149B2 (en) * | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| US11389449B2 (en) | 2017-09-14 | 2022-07-19 | Cyclerion Therapeutics, Inc. | Treatment of metabolic syndrome with an sGC stimulator |
| JP7542518B2 (ja) * | 2018-07-11 | 2024-08-30 | ティセント セラピューティクス インコーポレーテッド | ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用 |
| EA202190193A1 (ru) * | 2018-07-12 | 2021-06-16 | Бёрингер Ингельхайм Интернациональ Гмбх | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы |
| WO2021073643A1 (zh) * | 2019-10-18 | 2021-04-22 | 正大天晴药业集团股份有限公司 | 用于治疗非酒精性脂肪性肝炎的药物 |
| CN114727977A (zh) | 2019-11-19 | 2022-07-08 | 特维娜有限公司 | 化合物和化合物s1p1调节剂的制备方法 |
| WO2021167458A1 (en) * | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| WO2023143424A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种氮杂并环衍生物及其在医药上的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10109861A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| US20100144864A1 (en) * | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| JP5432890B2 (ja) | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| US9260424B2 (en) * | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| MX2012013574A (es) | 2010-05-26 | 2013-01-24 | Bayer Ip Gmbh | El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs). |
| DE102010021637A1 (de) * | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| CN102164320B (zh) | 2011-04-11 | 2016-06-22 | 北京数字太和科技有限责任公司 | 一种改进的基于条件接收技术的终端 |
| IL285564B2 (en) * | 2013-03-15 | 2024-06-01 | Cyclerion Therapeutics Inc | sGC Stimulators |
| EP3094327A1 (en) * | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| WO2015123090A1 (en) * | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| WO2016014463A1 (en) * | 2014-07-22 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
| MX389961B (es) * | 2015-11-30 | 2025-03-20 | Cyclerion Therapeutics Inc | Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). |
| AU2017216429B2 (en) | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| EP3458063A4 (en) | 2016-05-18 | 2020-02-26 | Merck Sharp & Dohme Corp. | METHOD FOR USE OF TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISEASES |
-
2017
- 2017-01-31 AU AU2017216429A patent/AU2017216429B2/en not_active Ceased
- 2017-01-31 IL IL260701A patent/IL260701B/en unknown
- 2017-01-31 EP EP17704916.0A patent/EP3411026B1/en active Active
- 2017-01-31 CN CN201780013129.8A patent/CN108697678A/zh active Pending
- 2017-01-31 JP JP2018559177A patent/JP7098214B2/ja active Active
- 2017-01-31 CA CA3012001A patent/CA3012001A1/en active Pending
- 2017-01-31 WO PCT/US2017/015749 patent/WO2017136309A1/en not_active Ceased
- 2017-01-31 MX MX2018009173A patent/MX386216B/es unknown
- 2017-01-31 US US16/074,357 patent/US11357777B2/en active Active
- 2017-01-31 BR BR112018015718A patent/BR112018015718A2/pt not_active Application Discontinuation
- 2017-01-31 CN CN202310699763.9A patent/CN116726178A/zh active Pending
- 2017-01-31 KR KR1020187024680A patent/KR20180104123A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507185A5 (enExample) | ||
| DK2041102T3 (en) | Inhibitors of human protein tyrosine phosphatase and methods of use | |
| AU2006245676B2 (en) | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | |
| IL186750A (en) | Patridines, their uses in preparing HCV replication inhibitors, their compositions and combinations | |
| JP2019502686A5 (enExample) | ||
| AU2018233975A1 (en) | Pharmaceutical compositions for combination therapy | |
| JP2018501276A5 (enExample) | ||
| RU2002129569A (ru) | Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора | |
| JP2008509187A5 (enExample) | ||
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2009121775A (ru) | Пиридильное неароматическое азот-содержащее гетероцикло-1-карбоксилатное производное | |
| JP2003515523A5 (enExample) | ||
| RU2006136881A (ru) | Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv | |
| RU2008141511A (ru) | Конденсированные гетероциклические соединения и их применение в качестве модуляторов mglur5 | |
| JP2016512547A (ja) | 線維症疾患の治療のための化合物 | |
| EP2455080A1 (en) | S1P1 receptor agonists for use in the treatment of multiple sclerosis | |
| AU2005282290B2 (en) | Combination of organic compounds | |
| BRPI0710675A2 (pt) | uso de inibidores de c-src em combinação com um composto pirimidilaminobenzamida para o tratamento de leucemia | |
| WO2010000030A1 (en) | Thiazopyrimidinones and uses thereof | |
| EP1742633A2 (en) | Use of c-kit inhibitors for treating fibrosis | |
| CN112384214A (zh) | 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑 | |
| EP1758654A1 (en) | Use of c-kit inhibitors for treating plasmodium related diseases | |
| US9050347B2 (en) | 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor | |
| JP2011526266A (ja) | 消化管の炎症状態の処置を目的とするオキサゾリジノン類 | |
| JP2017171579A (ja) | 新規テトラヒドロピリドピリミジノン誘導体 |